| Předmět: |
|
| Zdroj: |
Drug Week; 10/8/2024, p3213-3213, 1p |
| Abstrakt: |
A report from researchers at Halozyme Therapeutics Inc. discusses the findings of their study on hyaluronidase therapy. Hyaluronidase is an enzyme that breaks down a substance called hyaluronan, which forms a gel-like barrier in the body. The researchers found that the administration of recombinant human hyaluronidase PH20 (rHuPH20) can lead to the formation of anti-drug antibodies (ADAs), but these antibodies did not have any negative effects on fertility or fetal development in animal models. The study also demonstrated the favorable safety profile of rHuPH20 and ADAs in nonclinical models. The research concludes that there are substantial safety margins for clinically relevant doses of rHuPH20. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
